Abstract

Objective To investigate the clinical significance of mutant-allele tumor heterogeneity (MATH) levels in papillary thyroid carcinoma (PTC). Methods The sequencing data and clinical data of PTC were downloaded from the public data sets of The Cancer Genome Atlas (TCGA) and preprocessed. The correlation between MATH and clinicopathological features of PTC was analyzed. Kaplan-Meier survival analysis was used to verify the prognostic value of MATH in patients with PTC. Results MATH scores ranged from 2.57 to 93.72 in PTC patients, with an average of 29.45±16.19. The patients with an MATH score ≥ 29.45 were assigned to a high-MATH group, and those with an MATH score 0.05). MATH was not a significant predictor of overall survival (OS) in patients with PTC (P=0.4595). Whereas in PTC patients with BRAF mutation, the OS in patients with a high MATH score was significantly worse than that in patients with a low MATH score (P=0.0252). In PTC patients with wild-type BRAF, the OS was significantly better in patients with a high MATH score than in those with a low MATH (P=0.0495). Conclusion MATH can predict the prognosis of PTC patients with wild type or mutant BRAF, which can be used to guide clinical treatment. Key words: Mutation; Alleles; Tumor heterogeneity; Thyroid neoplasms; BRAF genotype; Overall survival

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.